On April 30, 2026, Hims & Hers Health (NYSE: HIMS) launched Testosterone Rx+, a once-daily oral pill combining the SERM enclomiphene with zinc, vitamins B6 and B12, and L-arginine — its second major testosterone product in eight months and the latest move in a pivot away from over-reliance on the increasingly crowded GLP-1 telehealth market. Eligible patients can also bundle in tadalafil for concurrent ED support, structuring the offering as a "men's natural T + libido stack" rather than as a TRT-replacement therapy. The company posted the launch on its newsroom blog and confirmed the formulation includes enclomiphene as the active driver of natural testosterone production.

Why It Matters

The release marks Hims's most aggressive bid yet to displace the traditional ED + TRT clinic model with a unified, doorstep-delivered men's sexual health stack — and to demonstrate to investors that the company can grow non-GLP-1 specialty revenue fast enough to offset GLP-1 margin compression. Enclomiphene-based combination products are also a leading edge of how compounding pharmacies and telehealth partners are exploiting the gap between FDA-approved TRT (which requires injection or transdermal delivery, plus a controlled substance schedule) and a bottle-of-pills consumer experience. Expect intensified FDA enforcement scrutiny on compounded testosterone combinations as the category scales, mirroring the agency's posture on compounded GLP-1s in 2024-25.

The pitch leans on enclomiphene's mechanism — it blocks estrogen receptors in the hypothalamus, prompting the body to increase its own LH/FSH and downstream testosterone output, in contrast to exogenous TRT (gels, injections) that suppress the HPG axis. Hims claims 95% of customers using its broader testosterone protocols saw an increase in T levels and 80% reached "optimal levels" within 60 days. The company labels Testosterone Rx+ as "not approved or evaluated for safety, effectiveness, or quality by the FDA" — standard disclaimer for compounded combination products dispensed through telehealth, but a meaningful caveat that distinguishes Rx+ from the FDA-approved oral testosterone (Marius Pharmaceuticals' KYZATREX) that Hims also sells exclusively under a separate 2025 partnership.

The market context: Hims is racing to diversify revenue as the GLP-1 era of compounded semaglutide closed in March 2026 with the company's settlement and supply deal with Novo Nordisk, leaving Hims as a branded-only GLP-1 distributor with margins squeezed by competition from Ro, Eli Lilly's LillyDirect, and Amazon One Medical. Investors have rewarded the diversification story: HIMS stock closed up over 3% on Thursday following Rx+ press, snapping a three-session losing streak. FY26 guidance issued in February calls for $2.7–2.9B in revenue and $300–375M adjusted EBITDA, with international expansion and new specialties (testosterone, mental health, longevity) cited as the principal growth vectors.

The launch also rides the regulatory tailwind from the FDA's late-2025/early-2026 signal encouraging sponsors of approved testosterone replacement therapies to pursue a new indication for low libido in men with idiopathic hypogonadism — a category that, if formally added to TRT product labels, could roughly double the addressable market for prescribed testosterone in the U.S. Telehealth incumbents (Hims, Ro, BlueChew) are positioning as the most likely beneficiaries since their direct-to-consumer model has been the dominant distribution channel for new male sexual health prescribing patterns.

Sources

Update — 2026-05-03

Initial entry — story first created.